Microsatellite Instability

• 

  Subject Areas on Research

  • A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803. 
  • Adenoma-like adenocarcinoma: a subtype of colorectal carcinoma with good prognosis, deceptive appearance on biopsy and frequent KRAS mutation. 
  • An integrated molecular profile of endometrioid ovarian cancer. 
  • Association between IHC and MSI testing to identify mismatch repair-deficient patients with ovarian cancer. 
  • Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. 
  • Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. 
  • Association of family history with cancer recurrence and survival among patients with stage III colon cancer. 
  • Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. 
  • Colon cancer with microsatellite instability in a 13-year-old Hispanic male. 
  • Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. 
  • Comprehensive Characterization of Cancer Driver Genes and Mutations. 
  • Correlation between germline mutations in MMR genes and microsatellite instability in ovarian cancer specimens. 
  • Deciphering Elevated Microsatellite Alterations at Selected Tetra/Pentanucleotide Repeats, Microsatellite Instability, and Loss of Heterozygosity in Colorectal Cancers. 
  • Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer. 
  • Differences in Microsatellite Instability Profiles between Endometrioid and Colorectal Cancers: A Potential Cause for False-Negative Results? 
  • Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. 
  • Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. 
  • Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. 
  • Gene expression analysis of tumor infiltrating lymphocyte markers in endometrial cancers indicates no significant increases in those cases with microsatellite instability. 
  • Hereditary prostate cancer as a feature of Lynch syndrome. 
  • Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. 
  • MSIseq: Software for Assessing Microsatellite Instability from Catalogs of Somatic Mutations. 
  • Microsatellite Instability Is Common in Colorectal Cancer in Native Nigerians. 
  • Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. 
  • Microsatellite instability is frequently observed in rectal cancer and influenced by neoadjuvant chemoradiation. 
  • Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. 
  • Molecular profile and copy number analysis of sporadic colorectal cancer in Taiwan. 
  • Molecular testing in colorectal cancer: diagnosis of Lynch syndrome and personalized cancer medicine. 
  • Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome. 
  • Next-Generation Sequencing Concordance Analysis of Comprehensive Solid Tumor Profiling between a Centralized Specialty Laboratory and the Decentralized Personal Genome Diagnostics elio Tissue Complete Kitted Solution. 
  • Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. 
  • PD-L1 Expression Patterns in Microsatellite Instability-High Intestinal Adenocarcinoma Subtypes. 
  • Personalized treatment in patients with colorectal liver metastases. 
  • Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. 
  • Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. 
  • Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer. 
  • Reply to S. Sorscher. 
  • Risk factors for ovarian cancers with and without microsatellite instability. 
  • Risk factors for ovarian cancers with and without microsatellite instability. 
  • Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer. 
  • Single-amplicon MSH2 A636P mutation testing in Ashkenazi Jewish patients with colorectal cancer: role in presurgical management. 
  • Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. 
  • Survival in women with ovarian cancer with and without microsatellite instability. 
  • Template for reporting results of biomarker testing of specimens from patients with carcinoma of the colon and rectum. 
  • The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform. 
  • Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice. 
  • Universal screening for Lynch syndrome in uterine cancer patients: A quality improvement initiative. 
  • Use of molecular biomarkers to inform adjuvant therapy for colon cancer. 
  • WRN helicase is a synthetic lethal target in microsatellite unstable cancers. 
  • Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management. 
  • Whole-genome reconstruction and mutational signatures in gastric cancer. 
  • p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Zafar, Syed Yousuf, Adjunct Professor in the Department of Medicine, Duke Science & Society